Fig. 3From: Trends in orphan medicinal products approvals in the European Union between 2010–2022Evolution of the number of non-orphan products which have received a non-standard marketing authorization, non-orphan products which are non-small molecules, and non-orphan products which have benefited from accelerated assessmentBack to article page